Showing results (71-80 of 6,003) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|July 17, 2019
Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast CancerTsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, et al.
Molecular Cancer Therapeutics|April 22, 2024
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid TumorsBertha L Rodriguez, Jiawei Huang, Laura Gibson, et al.
Molecular Cancer Therapeutics|April 22, 2024
SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib SensitivityNan Fang, Bing Liu, Qiuzhong Pan, et al.
Molecular Cancer Therapeutics|April 19, 2024
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia TreatmentManuela Bratti, Elisa Stubbs, Sergii Kolodych, et al.
Molecular Cancer Therapeutics|August 15, 2014
Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4DNingning He, Nayoung Kim, Mee Song, et al.
Molecular Cancer Therapeutics|August 15, 2014
Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumorZiyan Y Pessetto, Yan Ma, Jeff J Hirst, et al.
Molecular Cancer Therapeutics|August 15, 2014
Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1Carolina Castilla, M Luz Flores, Rafael Medina, et al.
Molecular Cancer Therapeutics|December 24, 2013
Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1αTian-Yu Cai, Xiao-Wen Liu, Hong Zhu, et al.
Molecular Cancer Therapeutics|December 17, 2013
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockadeJanet L Martin, Hasanthi C de Silva, Mike Z Lin, et al.
Molecular Cancer Therapeutics|December 21, 2013
Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibitionMelanie L Bailey, Nigel J O'Neil, Derek M van Pel, et al.
Pageof 601